Coagulation activation marker
biomarkers of blood signals
Coagulation activation markers are biomarkers of net activation of coagulation and fibrinolysis. Examples include prothrombin fragment 1+2 (F1+2), thrombin–antithrombin complex (TAT), fibrinopeptide A (FpA), fibrin monomers (FMs), plasmin-α2-antiplasmin complex (PAP), activated protein C–protein C inhibitor (APC-PCI), and D-dimer (DD). These compounds are markers of thrombin generation (F1+2, TAT, APC-PCI), fibrin generation (FpA, FMs), and fibrinolysis (DD, PAP). Coagulation activation markers, particularly D-dimer, are useful in the diagnosis of acute venous thromboembolism. They may also be useful in the assessment of hypercoagulability and venous thromboembolism risk.
Levels of coagulation activation markers are increased with pregnancy, with estrogen-containing birth control pills, with menopausal hormone therapy, and with high-dose parenteral estradiol therapy for prostate cancer. Transdermal estradiol appears to have less influence on coagulation activation markers than oral estrogens in menopausal hormone therapy. Birth control pills containing estradiol or estetrol also appear to have less influence on coagulation activation markers than ethinylestradiol-containing birth control pills.
Markers of platelet activation (primary hemostasis) include platelet factor 4 (PF4), β-thromboglobulin (β-TG), and P-selectin.
This brief starts where responsible research should: with the source description of “Coagulation activation marker” as biomarkers of blood signals. Everything that follows is an evidence route, not borrowed authority.
Why this record matters
The subject matters to the general reference register because the source frames it as biomarkers of blood signals. Its deeper value depends on whether names, dates, institutions and citations support that framing.
Vocabulary and entity names are the principal evidence signals here, because they determine the precision of every later search. The source revision retrieved here is dated Mar 4, 2026. The linked authority identifier is Q112030408. None of the 0 selected statements returned an explicit reference.
The absence of detail may reflect summary conventions rather than a lack of surviving documentation. The source lead contains qualifying language; that uncertainty should survive quotation, summary and reuse. Authority statements aid reconciliation but still require their own references, qualifiers and ranks to be checked.
How to read it
Use the entry as an orientation point, then follow its citations and revision history. Names, dates and institutional relationships should be checked against the original record.
- Subject orientation
- Search vocabulary
- Locating named sources
The closest primary source, responsible institution and strongest cited specialist reference.
Three-step research path
- Establish the record: confirm the title “Coagulation activation marker”, its source revision and the description used here.
- Expand the search: follow Coagulation activation marker primary sources, Coagulation activation marker archive and Coagulation research across catalogues and specialist indexes.
- Test the account: compare the strongest cited source with the responsible institution’s current record and note any disagreement.
Questions for further research
- Which source most directly establishes the central claim about “Coagulation activation marker”?
- Which cited source is closest to the event, object or claim?
- What terminology or title could unlock a more precise catalogue search?
Search terms from this dossier
This entry incorporates text from “Coagulation activation marker” on English Wikipedia. Contributors are listed in the page history. Text is available under the Creative Commons Attribution-ShareAlike 4.0 License. Selected authority identifiers and statements are retrieved from Wikidata under CC0; their references and qualifiers remain part of the verification path.